Septerna (SEPN) Net Income towards Common Stockholders (2023 - 2026)
Septerna (SEPN) recorded quarterly Net Income towards Common Stockholders of -$8.6 million in Q1 2026, up 19.57% quarter-over-quarter from -$10.7 million in Q4 2025, and up 59.78% on a YoY basis from -$5.4 million in Q1 2025.
Septerna (SEPN) Net Income towards Common Stockholders (2023 - 2026) Analysis & Trends
Septerna's Net Income towards Common Stockholders history runs 4 years deep, the most recent figure standing at -$8.6 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 59.78% year-over-year to -$8.6 million; the TTM figure through Mar 2026 stood at -$36.0 million (up 54.57% YoY), while the FY2025 annual figure was -$48.9 million, up 31.92% from the prior year.
- Net Income towards Common Stockholders was -$8.6 million for Q1 2026 at Septerna, up from -$10.7 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $8.2 million in Q3 2025 to a low of -$24.8 million in Q2 2025.
- Historically, Net Income towards Common Stockholders has averaged -$14.4 million across 4 years, with a median of -$16.7 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders sank 87.51% in 2024, then soared 139.82% in 2025.
- A 4-year view of Net Income towards Common Stockholders shows it stood at -$18.2 million in 2023, then slipped by 13.85% to -$20.7 million in 2024, then jumped by 48.05% to -$10.7 million in 2025, then rose by 19.57% to -$8.6 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$8.6 million (Q1 2026), -$10.7 million (Q4 2025), and $8.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Septerna | 1.62 Bn | 1.62 Bn | - | -8.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.64 Mn |
| Dec 31, 2025 | -10.74 Mn |
| Sep 30, 2025 | 8.17 Mn |
| Jun 30, 2025 | -24.84 Mn |
| Mar 31, 2025 | -21.48 Mn |
| Dec 31, 2024 | -20.67 Mn |
| Sep 30, 2024 | -20.52 Mn |
| Jun 30, 2024 | -16.66 Mn |
| Mar 31, 2024 | -14.35 Mn |
| Dec 31, 2023 | -18.15 Mn |
| Sep 30, 2023 | -10.95 Mn |